PaxMedica, Inc. is a forward-looking clinical-stage biopharmaceutical firm specializing in cutting-edge anti-purinergic drug therapies (APT) aimed at addressing a range of challenging neurologic disorders, including Autism Spectrum Disorder (ASD) and Human African Trypanosomiasis (HAT). Our portfolio encompasses critical areas within the neurology field, with a focus on pioneering advancements in both ASD and HAT treatments. We are dedicated to the continuous development and evaluation of our pioneering program, PAX-101-an intravenous suramin formulation that lies at the heart of our efforts, particularly focused on innovative ASD and HAT treatment solutions. Our ongoing research initiatives not only prioritize the needs of ASD and HAT patients but also extend to exploring potential therapeutic applications for related conditions.
Company profile
Ticker
PXMD
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
PXMD stock data
Latest filings (excl ownership)
8-K
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
16 Apr 24
ARS
2023 FY
Annual report to shareholders
15 Apr 24
DEF 14A
Definitive proxy
15 Apr 24
8-K
PaxMedica Achieves Key Milestone in the Development of PAX-101
11 Apr 24
PRE 14A
Preliminary proxy
3 Apr 24
8-K
Amendments to Articles of Incorporation or Bylaws
22 Mar 24
8-K
PXMD Investor Presentation February 2024 © 2024. PaxMedica, Inc. Proprietary Information. All rights reserved. v3
13 Mar 24
10-K
2023 FY
Annual report
11 Mar 24
8-K
Departure of Directors or Certain Officers
29 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12 Jan 24
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.15 mm | 1.15 mm | 1.15 mm | 1.15 mm | 1.15 mm | 1.15 mm |
Cash burn (monthly) | 638.98 k | 367.53 k | 1.45 mm | 1.39 mm | (no burn) | 205.69 k |
Cash used (since last report) | 4.26 mm | 2.45 mm | 9.69 mm | 9.29 mm | n/a | 1.37 mm |
Cash remaining | -3.11 mm | -1.30 mm | -8.54 mm | -8.14 mm | n/a | -217.76 k |
Runway (months of cash) | -4.9 | -3.5 | -5.9 | -5.8 | n/a | -1.1 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 10 |
Opened positions | 5 |
Closed positions | 4 |
Increased positions | 1 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 32.43 mm |
Total shares | 8.63 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
TardiMed Sciences | 7.34 mm | $0.00 |
Blue Cane Partners | 1.18 mm | $0.00 |
Clearstead Advisors | 38.16 k | $10.92 mm |
Susquehanna International | 31.03 k | $9.22 mm |
Geode Capital Management | 30.78 k | $9.14 mm |
HRT Financial | 10.77 k | $3.00 k |
Tower Research Capital | 7.89 k | $2.26 mm |
Advisor | 2.00 k | $572.00 k |
UBS UBS Group AG - Registered Shares | 1.10 k | $314.00 k |
WFC Wells Fargo & Co. | 35.00 | $10.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Mar 24 | Casamento Charles J | Common Stock | Payment of exercise | Dispose F | No | No | 0.69 | 992 | 684.48 | 2,386 |
12 Mar 24 | Zachary Rome | Common Stock | Payment of exercise | Dispose F | No | No | 0.69 | 4,904 | 3.38 k | 10,244 |
12 Mar 24 | Karen LaRochelle | Common Stock | Payment of exercise | Dispose F | No | No | 0.69 | 604 | 416.76 | 2,225 |
12 Mar 24 | Stephen Sheldon | Common Stock | Payment of exercise | Dispose F | No | No | 0.69 | 3,356 | 2.32 k | 10,137 |
12 Mar 24 | David W. Hough | Common Stock | Payment of exercise | Dispose F | No | No | 0.69 | 1,452 | 1.00 k | 5,905 |
News
12 Health Care Stocks Moving In Friday's Pre-Market Session
19 Apr 24
PaxMedica Receives Emergency Request For IV Suramin From African Health Ministry For Use In Treating Fatal Sleeping Sickness
16 Apr 24
12 Health Care Stocks Moving In Tuesday's After-Market Session
16 Apr 24
12 Health Care Stocks Moving In Tuesday's Intraday Session
16 Apr 24
Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings
15 Apr 24
Press releases
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
16 Apr 24
PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission
11 Apr 24
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments
13 Mar 24